We begin this week with news from CRO Chiltern International who has appointed Dr. Andrew Monaghan as Director, Global Pharmacovigilance in order to lead the team and expand the organization's global pharmacovigilance offering.
Monaghan comes from global head of safety operations at Roche Products, UK and has over 30 years of experience in the business.
“His strong leadership skills and extensive clinical experience will ensure our clients continue to receive customized and efficient safety solutions to meet their specific product and regulatory requirements, whether with investigational or postmarketed products,” said Chiltern Executive VP, Global Medical and Regulatory Affairs, Sharon Moore.
And read here about Chiltern’s significant growth in the last quarter.
There is a new Vice President Human Resources & Communications at DSM Pharmaceutical Products - the contract manufacturing arm of Royal DSM – in the form of Dr. Veronika Zuegel.
Zuegel, with over 20 years of experience in HR, comes to DSM from a series of executive positions at Constantia Packaging and Alcoa.
And DSM upped its biologics offerings back in April when it opened a new mammalian cell culture facility in Australia. Read about it here.
Former Group R&D Director of Wellcome and Director General of the Association of the British Pharmaceutical Industry (ABPI), Prof Trevor M Jones CBE has been appointed non-executive Chairman of the Board of Directors at Simbec Research.
He “has a proven successful track record over 30 years in providing key clinical research expertise to global and UK based pharmaceutical and biotech companies,” said Prof Sir Chris Evans, from Arthurian and Chairman of the Welsh Life Sciences Hub. “This investment is a clear statement of the confidence we have in the future of Life Sciences in Wales.”
Next to Frontage Laboratories and Dr. Cheryl Li has been appointed Senior Vice President, Global CMC Services, forming part of Frontage’s corporate strategic expansion in CMC infrastructure to meet growing development needs in novel drugs, generic products and biosimilars.
Li held several management positions at Johnson & Johnson before coming to Frontage and has also worked for Covidien and AMRI.
Dr. Song Li, Chairman and CEO of Frontage said: “I’m confident that Frontage will significantly benefit from her broad technical knowledge, global industry network, and business experience driving strong collaborations as the company enters its next phase of growth.”
And finally… Healthcare advertising services firm Abelson Taylor has appointed two new senior account executives.
Kathleen Curley, who joined the firm in 2010, will focus on neurology and rheumatology accounts.
Meghan Mulhern, who has been with the firm since 2009, will be working on a portfolio of products for the treatment of diabetes.